三阴性乳腺癌组织学亚型对预后的影响

IF 2.7 2区 医学 Q2 PATHOLOGY Human pathology Pub Date : 2024-08-10 DOI:10.1016/j.humpath.2024.105640
Claudia Grosse , Petar Noack , Alexandra Grosse , Caroline Ines Preuss , Heike Kathleen Schwarz , Thomas Gitter , Peter Schrenk , Heike Frauchiger-Heuer , Bärbel Papassotiropoulos , Christoph Tausch , Umberto Maccio , Holger Moch , Rupert Langer , Zsuzsanna Varga
{"title":"三阴性乳腺癌组织学亚型对预后的影响","authors":"Claudia Grosse ,&nbsp;Petar Noack ,&nbsp;Alexandra Grosse ,&nbsp;Caroline Ines Preuss ,&nbsp;Heike Kathleen Schwarz ,&nbsp;Thomas Gitter ,&nbsp;Peter Schrenk ,&nbsp;Heike Frauchiger-Heuer ,&nbsp;Bärbel Papassotiropoulos ,&nbsp;Christoph Tausch ,&nbsp;Umberto Maccio ,&nbsp;Holger Moch ,&nbsp;Rupert Langer ,&nbsp;Zsuzsanna Varga","doi":"10.1016/j.humpath.2024.105640","DOIUrl":null,"url":null,"abstract":"<div><p>The impact of special histological types (ST) in triple-negative breast cancer (TNBC) and its association with overall outcome has gained increasing relevance as survival has been linked to specific histological TNBC subtypes. We evaluated the clinicopathological and survival data of 598 patients with 613 TNBCs, including 464 TNBCs of no special type (NST) and 149 TNBCs ST (low-grade, n = 12, 8.1%; high-grade, n = 112, 75.2%; apocrine and androgen receptor-positive [APO AR], n = 25, 16.8%). Patients with low-grade TNBC ST and TNBC ST APO AR were significantly older (<em>P</em> &lt; 0.001) and had a lower Ki67 index (<em>P</em> &lt; 0.001) than those with TNBC NST. Patients with high-grade TNBC ST were significantly older (<em>P</em> = 0.006) and had poorer pathological responses to neoadjuvant chemotherapy (NAC) (<em>P</em> &lt; 0.001) than those with TNBC NST. Significant survival differences were observed between low-grade TNBC ST, TNBC ST APO AR, high-grade TNBC ST, and TNBC NST in the entire study group (DFS, <em>P</em> = 0.002; DDFS, <em>P</em> = 0.001) and in the non-NAC subgroup (OS, <em>P</em> = 0.034; DFS, <em>P</em> = 0.001; DDFS, <em>P</em> &lt; 0.001). Patients with low-grade TNBC ST had the best survival outcomes. Patients with high-grade TNBC ST showed significantly worse outcomes than those with TNBC NST (entire study group: OS, <em>P</em> = 0.049; DFS, <em>P</em> &lt; 0.001; DDFS, <em>P</em> = 0.001; non-NAC subgroup: OS, <em>P</em> = 0.014; DFS, <em>P</em> &lt; 0.001; DDFS, <em>P</em> &lt; 0.001). We conclude that prognostic stratification of TNBC ST is ultimately important for optimizing the therapeutic management of patients with these rare tumor entities.</p></div>","PeriodicalId":13062,"journal":{"name":"Human pathology","volume":"152 ","pages":"Article 105640"},"PeriodicalIF":2.7000,"publicationDate":"2024-08-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0046817724001497/pdfft?md5=cfd7d47b57341ac2977bc52ec60208e1&pid=1-s2.0-S0046817724001497-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Prognostic impact of histological subtyping in triple-negative breast cancer\",\"authors\":\"Claudia Grosse ,&nbsp;Petar Noack ,&nbsp;Alexandra Grosse ,&nbsp;Caroline Ines Preuss ,&nbsp;Heike Kathleen Schwarz ,&nbsp;Thomas Gitter ,&nbsp;Peter Schrenk ,&nbsp;Heike Frauchiger-Heuer ,&nbsp;Bärbel Papassotiropoulos ,&nbsp;Christoph Tausch ,&nbsp;Umberto Maccio ,&nbsp;Holger Moch ,&nbsp;Rupert Langer ,&nbsp;Zsuzsanna Varga\",\"doi\":\"10.1016/j.humpath.2024.105640\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>The impact of special histological types (ST) in triple-negative breast cancer (TNBC) and its association with overall outcome has gained increasing relevance as survival has been linked to specific histological TNBC subtypes. We evaluated the clinicopathological and survival data of 598 patients with 613 TNBCs, including 464 TNBCs of no special type (NST) and 149 TNBCs ST (low-grade, n = 12, 8.1%; high-grade, n = 112, 75.2%; apocrine and androgen receptor-positive [APO AR], n = 25, 16.8%). Patients with low-grade TNBC ST and TNBC ST APO AR were significantly older (<em>P</em> &lt; 0.001) and had a lower Ki67 index (<em>P</em> &lt; 0.001) than those with TNBC NST. Patients with high-grade TNBC ST were significantly older (<em>P</em> = 0.006) and had poorer pathological responses to neoadjuvant chemotherapy (NAC) (<em>P</em> &lt; 0.001) than those with TNBC NST. Significant survival differences were observed between low-grade TNBC ST, TNBC ST APO AR, high-grade TNBC ST, and TNBC NST in the entire study group (DFS, <em>P</em> = 0.002; DDFS, <em>P</em> = 0.001) and in the non-NAC subgroup (OS, <em>P</em> = 0.034; DFS, <em>P</em> = 0.001; DDFS, <em>P</em> &lt; 0.001). Patients with low-grade TNBC ST had the best survival outcomes. Patients with high-grade TNBC ST showed significantly worse outcomes than those with TNBC NST (entire study group: OS, <em>P</em> = 0.049; DFS, <em>P</em> &lt; 0.001; DDFS, <em>P</em> = 0.001; non-NAC subgroup: OS, <em>P</em> = 0.014; DFS, <em>P</em> &lt; 0.001; DDFS, <em>P</em> &lt; 0.001). We conclude that prognostic stratification of TNBC ST is ultimately important for optimizing the therapeutic management of patients with these rare tumor entities.</p></div>\",\"PeriodicalId\":13062,\"journal\":{\"name\":\"Human pathology\",\"volume\":\"152 \",\"pages\":\"Article 105640\"},\"PeriodicalIF\":2.7000,\"publicationDate\":\"2024-08-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S0046817724001497/pdfft?md5=cfd7d47b57341ac2977bc52ec60208e1&pid=1-s2.0-S0046817724001497-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Human pathology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0046817724001497\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"PATHOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Human pathology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0046817724001497","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PATHOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

三阴性乳腺癌(TNBC)中特殊组织学类型(ST)的影响及其与总体预后的关系变得越来越重要,因为生存率与特定组织学TNBC亚型有关。我们评估了598例613型TNBC患者的临床病理和生存数据,其中包括464例无特殊类型(NST)TNBC和149例ST型TNBC(低分化,12例,占8.1%;高分化,112例,占75.2%;无分泌和雄激素受体阳性[APO AR],25例,占16.8%)。低分化TNBC ST和TNBC ST APO AR患者的年龄(P<0.001)和Ki67指数(P<0.001)明显低于TNBC NST患者。与TNBC NST患者相比,高级别TNBC ST患者的年龄明显偏大(P = 0.006),对新辅助化疗(NAC)的病理反应较差(P < 0.001)。在整个研究组(DFS,P = 0.002;DDFS,P = 0.001)和非NAC亚组(OS,P = 0.034;DFS,P = 0.001;DDFS,P < 0.001)中,低级别TNBC ST、TNBC ST APO AR、高级别TNBC ST和TNBC NST之间存在显著的生存差异。低分化TNBC ST患者的生存预后最好。高级别TNBC ST患者的预后明显差于TNBC NST患者(整个研究组:OS,P = 0.049;DFS,P = 0.001;DDFS,P < 0.001):OS,P = 0.049;DFS,P < 0.001;DDFS,P = 0.001;非 NAC 亚组:OS,P = 0.014;DFS,P < 0.001;DDFS,P < 0.001)。我们的结论是,TNBC ST 的预后分层对于优化这些罕见肿瘤实体患者的治疗管理至关重要。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Prognostic impact of histological subtyping in triple-negative breast cancer

The impact of special histological types (ST) in triple-negative breast cancer (TNBC) and its association with overall outcome has gained increasing relevance as survival has been linked to specific histological TNBC subtypes. We evaluated the clinicopathological and survival data of 598 patients with 613 TNBCs, including 464 TNBCs of no special type (NST) and 149 TNBCs ST (low-grade, n = 12, 8.1%; high-grade, n = 112, 75.2%; apocrine and androgen receptor-positive [APO AR], n = 25, 16.8%). Patients with low-grade TNBC ST and TNBC ST APO AR were significantly older (P < 0.001) and had a lower Ki67 index (P < 0.001) than those with TNBC NST. Patients with high-grade TNBC ST were significantly older (P = 0.006) and had poorer pathological responses to neoadjuvant chemotherapy (NAC) (P < 0.001) than those with TNBC NST. Significant survival differences were observed between low-grade TNBC ST, TNBC ST APO AR, high-grade TNBC ST, and TNBC NST in the entire study group (DFS, P = 0.002; DDFS, P = 0.001) and in the non-NAC subgroup (OS, P = 0.034; DFS, P = 0.001; DDFS, P < 0.001). Patients with low-grade TNBC ST had the best survival outcomes. Patients with high-grade TNBC ST showed significantly worse outcomes than those with TNBC NST (entire study group: OS, P = 0.049; DFS, P < 0.001; DDFS, P = 0.001; non-NAC subgroup: OS, P = 0.014; DFS, P < 0.001; DDFS, P < 0.001). We conclude that prognostic stratification of TNBC ST is ultimately important for optimizing the therapeutic management of patients with these rare tumor entities.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Human pathology
Human pathology 医学-病理学
CiteScore
5.30
自引率
6.10%
发文量
206
审稿时长
21 days
期刊介绍: Human Pathology is designed to bring information of clinicopathologic significance to human disease to the laboratory and clinical physician. It presents information drawn from morphologic and clinical laboratory studies with direct relevance to the understanding of human diseases. Papers published concern morphologic and clinicopathologic observations, reviews of diseases, analyses of problems in pathology, significant collections of case material and advances in concepts or techniques of value in the analysis and diagnosis of disease. Theoretical and experimental pathology and molecular biology pertinent to human disease are included. This critical journal is well illustrated with exceptional reproductions of photomicrographs and microscopic anatomy.
期刊最新文献
Angioimmunoblastic T-cell Lymphoma: Current Diagnostic Insights and Advances. Cyclin D1-negative Mantle Cell Lymphoma. Epstein-Barr Virus-Associated B-cell Lymphoproliferative Disorders and Lymphomas: Diagnostic Overlaps and Defining Features. Genetic Validation of a TSC2 Immunohistochemistry Assay in TSC/mTOR-pathway Altered Renal Tumors. PAX6 is a useful marker for pancreatic origin of neuroendocrine neoplasms: A tissue microarray study evaluating more than 19,000 tumors from 150 different tumor types.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1